Share this article

Gilead Sciences and Jounce Therapeutics have amended their current license agreement for first-in-class immunotherapy, GS-1811 (formerly JTX-1811).

The initial license agreement was signed in 2020.

The amended agreement will allow Gilead Sciences to acquire all the remaining rights for GS-1811 from Jounce Therapeutics.

Certain operational obligations of the companies that are related to GS-1811 have also been terminated as part of the transaction.

Pursuant to the deal, Gilead will also buy certain related intellectual property along with all the outstanding rights to GS-1811 from Jounce.

Now, the company will be solely responsible for all further research, development, and commercialisation of GS-1811 across the world.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

For the deal, Jounce will receive $67m from Gilead and is no longer entitled to receive the remaining contingent payments of up to $645m in milestones and royalties under the original agreement.

Gilead Oncology Therapeutic Area head senior vice president Bill Grossman said: “Today’s news about GS-1811 further demonstrates our commitment to our rapidly evolving oncology franchise and mission of pioneering next-generation medicines for people with cancer.

“GS-1811, with its potential new pathway of activating the immune system, gives us the opportunity to potentially change the standard of care with a treatment that works from inside cancerous cells to shrink solid tumours.”

The anti-CCR8 antibody, GS-1811 has been designed to reduce immunosuppressive tumour-infiltrating T regulatory cells selectively in the tumour microenvironment.

It is currently being evaluated in Phase I clinical trial for the treatment of solid tumours.

Jounce CEO and president Richard Murray said: “This transaction allows us to extend our runway and remain focused on delivering meaningful and long-lasting benefits to cancer patients.”